News

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

Scott Leffler Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler…

4 months ago

Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea

-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive…

4 months ago

BioAdaptives, Inc. to Form New Division, AI BodyShape Lab, to Promote Adult Fitness and Weight Management

BioAdaptives, Inc. BioAdaptives’ AI-based Fit Your Outfit app LAS VEGAS, NV, Dec. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –…

4 months ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating…

4 months ago

DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI

Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generationSAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE)…

4 months ago

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL);…

4 months ago

Microbix Reports Results for Q4 & Full-Year Fiscal 2023

Full-Year Sales of $16.5 million and Net Loss of $0.04 millionMISSISSAUGA, Ontario, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems…

4 months ago

ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today…

4 months ago

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing…

4 months ago

Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the…

4 months ago